Intercept Pharmaceuticals Logo
US45845P1084
A1J5U0
ICPT

Intercept Pharmaceuticals

Forecast

The analysts' average price target is €20.15 (+15.01%). The median is €17.32 (-1.14%).

Buy
  16
Hold
  19
Sell
  5

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last year, Intercept Pharmaceuticals had revenue of €266.35m and net profit of €107.37m

(EUR) 2022
YoY
Revenue 266.35m 16.67%
Gross profit 265.44m 16.24%
Net profit 107.37m 184.19%
EBITDA -142.52m 376.27%

Fundamentals

Metric Value
Market capitalization
€724.24m
Number of shares
41.83m
52-week high/low
€19.92 - €8.04
Dividends No
Beta
0.88
P/E ratio
5.57
PEG ratio
-0.04
P/B ratio
6.90
P/S ratio
2.78

Company profile

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.

Name
Intercept Pharmaceuticals
CEO
Jerome B. Durso
Headquarters New York City, ny
USA
Website
Sector
Materials
Industry
Chemicals
IPO
11/10/2012
Employees 341

Ticker symbols

Exchange Symbol
NASDAQ
ICPT
🍪

Parqet  uses cookies. Learn more